[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolically-obese-normal-weight\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolically-obese-normal-weight":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100620508","metabolic-obesity-in-normal-weight-monw-diagnostic-markers-stud-100620508",false,"NCT07358533","Metabolic Obesity in Normal Weight (MONW): Diagnostic Markers Stud","Disorders Hidden Under the Guise of BMI - Metabolic Obesity in People With Normal Body Weight (MONW) - the Search for Diagnostic Markers and Its Consequences for Health","Inclusion Criteria:\n\n* Written, informed consent to participate in the research.\n* Gender: Female.\n* Age 18-35 years.\n* BMI in the range of 18.5-25 kg\u002Fm².\n\nExclusion Criteria:\n\n* Thyroid disease.\n* Pregnancy or breastfeeding.\n* Eating disorders.\n* Polycystic ovary syndrome (PCOS).\n* Hormone therapy and\u002For use of hormonal contraceptives.\n* Smoking.\n* Metal or silicone implants (contraindication for DXA\u002Fbody composition accuracy).\n* Vitamin and\u002For mineral supplementation.\n* Acute and\u002For chronic illnesses.\n* Type I or II diabetes, dyslipidemia, hypertension.\n* Use of hypolipemic, antihypertensive, antiglycemic, or insulin medications.",true,"FEMALE","18 Years","35 Years",{"count":21,"type":22},176,"ESTIMATED","OBSERVATIONAL","Metabolically Obese Normal Weight (MONW) represents a phenotype affecting individuals with a normal Body Mass Index (BMI) but characterized by excessive adipose tissue accumulation. This condition is associated with increased cardiovascular risk, insulin resistance, and endothelial dysfunction, yet remains underdiagnosed.\n\nThis observational longitudinal study aims to comprehensively evaluate the relationship between excessive adipose tissue deposition, endothelial dysfunction, and asprosin concentrations in young women. The study will recruit 176 healthy women aged 18-35 years with normal BMI (\\\u003C25 kg\u002Fm²). Participants will be divided into two groups based on body fat percentage (PBF) assessed by dual-energy X-ray absorptiometry (DXA): the MONW group (PBF ≥ 35.78%) and the Control group (PBF \\\u003C 35.78%).\n\nThe specific objectives of the study include:\n\n* Assessment of vascular endothelial function using flow-mediated dilation (FMD) of the brachial artery.\n* Evaluation of asprosin as a novel biomarker in the MONW phenotype.\n* Analysis of biochemical indices including asymmetric dimethylarginine (ADMA) and von Willebrand factor (vWF).\n* Advanced metabolomic profiling to identify metabolic signatures.\n\nParticipants will undergo anthropometric measurements, body composition analysis (DXA), and blood sampling for biochemical and hormonal analyses. The study aims to develop predictive models for early cardiovascular risk detection in normal-weight individuals.",[26,27,28],"Normal Weight Obesity","Metabolically Obese Normal Weight","Metabolic Syndrome",[30,31,32,33,34,35,36],"Endothelial Dysfunction","Metabolic Disorders","Visceral Adiposity","Flow-Mediated Dilation","Metabolomics","Asprosin","Normal Weight","NOT_YET_RECRUITING","2026-01-21",{"date":40,"type":41},"2026-01-23","ACTUAL",{"date":43,"type":22},"2026-09",{"date":45,"type":22},"2029-09",{"name":47,"class":48},"Pomeranian Medical University Szczecin","OTHER"]